Skip to Main Content
Leo Buckley, Pharm.D.

Leo Buckley, Pharm.D.

Titles and Appointments

Assistant Professor

School
Medical School
Department
Internal Medicine | Public Health
  • Biography

    Leo F. Buckley, PharmD, MPH is a cardiovascular pharmacotherapy researcher and clinician whose work bridges molecular discovery with clinical implementation to improve heart failure prevention and treatment. He completed Pharmacy Practice and Cardiovascular Pharmacotherapy residencies at Brigham and Women's Hospital in his hometown Boston, MA, an Experimental Cardiovascular Pharmacotherapy fellowship at Virginia Commonwealth University and an MPH with a concentration in Clinical Effectiveness at Harvard TH Chan School of Public Health. Prior to joining the UT Southwestern faculty in 2025, he served as a Clinical Pharmacy Specialist and Clinical Investigator in the Department of Pharmacy at Brigham and Women's Hospital.

    His clinical research program integrates mechanistic clinical trials, epidemiology and advanced multi-omics (pharmaco-genomics/-proteomics/-metabolomics and single-cell analysis) to define how drugs modulate cardiac structure and function with the overall goal of developing novel, precision therapeutics for the prevention and treatment of heart failure. Current areas of emphasis include: defining the effects of iron repletion on cardiac structure, function, and energetics; elucidating molecular mechanisms of colchicine and anti-cytokine therapies; applying genomic, proteomic, metabolomic and single-cell analysis data to optimize cardiovascular drug interventions.

    Clinically, he practices in the Cardiomyopathy and Heart Failure Clinic, providing evidence-based pharmacotherapy for patients with complex cardiomyopathies.

  • Research Interest
    • Colchicine
    • Epidemiology
    • Genomics
    • Iron Deficiency
    • Metabolomics
    • Pharmacogenomics
    • Proteomics
    • Single-Cell Analysis
  • Publications

    Star Featured Publications

    Featured Featured Featured
    Hepcidin, incident heart failure, and cardiac dysfunction in older adults: the ARIC study.
    Aboelsaad IAF, Claggett BL, Lamberson V, Dorbala P, Matsushita K, Lutsey P, Yu B, Lennep BW, Farag YMK, Shah AM, Buckley LF, Eur J Prev Cardiol 2025 Aug 32 11 993-1000
    Potential Impact of Colchicine on Atherosclerotic Cardiovascular Disease in the United States.
    Buckley LF, Chebrolu B, Al Zaria M, Blankstein R, Libby P, Weber BN, JACC Adv 2025 Mar 4 3 101622
    Absolute and Functional Iron Deficiency in the US, 2017-2020.
    Tawfik YMK, Billingsley H, Bhatt AS, Aboelsaad I, Al-Khezi OS, Lutsey PL, Buckley LF, JAMA Netw Open 2024 Sep 7 9 e2433126
    Drug-Drug Interactions and the Clinical Tolerability of Colchicine Among Patients With COVID-19: A Secondary Analysis of the COLCORONA Randomized Clinical Trial.
    Alfehaid LS, Farah S, Omer A, Weber BN, Alkhezi O, Tawfik YMK, Shah AM, Libby P, Buckley LF, JAMA Netw Open 2024 Sep 7 9 e2431309
    Plasma Ferritin Levels, Incident Heart Failure, and Cardiac Structure and Function: The ARIC Study.
    Aboelsaad IAF, Claggett BL, Arthur V, Dorbala P, Matsushita K, Lennep BW, Yu B, Lutsey PL, Ndumele CE, Farag YMK, Shah AM, Buckley LF, JACC Heart Fail 2023 Dec
    Chronic Kidney Disease, Heart Failure, and Adverse Cardiac Remodeling in Older Adults: The ARIC Study.
    Buckley LF, Claggett BL, Matsushita K, McMahon GM, Skali H, Coresh J, Folsom AR, Konety SH, Wagenknecht LE, Mosley TH, Shah AM, JACC Heart Fail 2023 May 11 5 523-537
    Associations Between Kidney Histopathologic Lesions and Incident Cardiovascular Disease in Adults With Chronic Kidney Disease.
    Buckley LF, Schmidt IM, Verma A, Palsson R, Adam D, Shah AM, Srivastava A, Waikar SS, JAMA Cardiol 2023 Apr 8 4 357-365